Soliris Market 2026–2030: Emerging Trends and Forecast Opportunities

Uncover key drivers, emerging technologies, and competitive movements shaping the soliris market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Soliris Market in 2030?

The Soliris market size has shown substantial growth over recent years. It is anticipated to expand from $2030.44 million in 2025 to $2191.9 million in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. The expansion observed in the past can be attributed to several factors including unmet needs in rare diseases, successful clinical outcomes in PNH and aHUS, regulatory incentives for orphan drugs, improved patient survival rates, and a limited array of therapeutic alternatives.

The soliris market size is projected to experience significant expansion in the coming years. It is forecast to reach $2941.58 million by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. This growth during the forecast period can be attributed to factors such as the expansion into additional complement-mediated diseases, an increase in rare disease awareness, advancements in genetic diagnostics, enhanced healthcare funding for orphan drugs, and the implementation of long-term therapy adherence programs. Prominent trends observed during this period include the rising adoption of complement inhibitor therapies, an increased focus on ultra-rare diseases, the broader use of long-term biologic treatments, more widespread genetic testing for rare disorders, and the overall growth of the high-value orphan drug market.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19933&type=smp

What Drivers Are Influencing Production Trends In The Soliris Market?

The Soliris market is projected to grow due to the increasing occurrence of rare blood disorders. These disorders are uncommon conditions affecting the blood’s production, components, or clotting, such as hemophilia, sickle cell anemia, and thalassemia. The rise in their prevalence is attributed to improved diagnostic techniques, greater awareness, and genetic and environmental factors. Soliris aids patients with these conditions by inhibiting complement protein C5, which prevents excessive complement activation. This action reduces the risk of severe complications like hemolysis and organ damage, thereby enhancing overall disease management and patient outcomes. For instance, in May 2024, according to the National Health Service (NHS) England, a UK-based government-funded healthcare system, approximately 17,000 people were living with sickle cell disease, an inherited blood disorder, in England, with around 250 new cases diagnosed annually. Therefore, the increasing prevalence of rare blood disorders is driving the growth of the Soliris market.

Which Segments Are Gaining Traction In The Soliris Market?

The soliris market covered in this report is segmented –

1) By Type: Plasma Exchange, Plasma Infusion

2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (AHUS)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Trends Are Projected To Support The Growth Of The Soliris Market?

A significant trend in the Soliris market centers on developing biologic medicines for neuromyelitis optica spectrum disorder (NMOSD), intending to bolster treatment options for rare blood disorders. This constitutes a considerable stride forward in managing NMOSD, a rare and debilitating autoimmune condition affecting the central nervous system, by offering an effective therapy to diminish relapses and prevent further neurological damage. For instance, in October 2023, AstraZeneca PLC, a UK-based pharmaceutical company, obtained approval for Soliris (eculizumab) from the National Medical Products Administration (NMPA) in China for treating adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are positive for anti-aquaporin-4 (AQP4) antibodies (Ab+). This establishes Soliris as the first and only complement inhibitor approved for NMOSD treatment in China.

Who Are The Core Companies Influencing Trends In The Soliris Market?

Major companies operating in the soliris market are Pfizer

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/soliris-global-market-report

Which Regions Are Projected To Dominate The Soliris Market In The Coming Years?

North America was the largest region in the Soliris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Soliris Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19933&type=smp

Browse Through More Reports Similar to the Global Soliris Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Membrane Filtration Market Report 2026

https://www.thebusinessresearchcompany.com/report/membrane-filtration-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795